Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.K.’s NICE Plans Office To Help Drugs Gain Coverage Faster

Executive Summary

NICE is responding to a government consultation on how the cost-effectiveness watchdog should update its methodologies and processes in evaluating new products by opening a new Office for Market Access, which it says will help life sciences companies prepare for its appraisals and better their chances for coverage.

You may also be interested in...



Ebola Threat Prompts EU To Focus On Adaptive Licensing

The spread of Ebola to Europe is prompting regulators and industry to explore in more detail adaptive licensing pathways to speed access to potentially life-saving drugs.

US FDA Extends Roche’s Risdiplam Decision Date

The submission of more trial data from Roche has prompted the US FDA to extend by three months its decision on whether to approve risdiplam for spinal muscular atrophy.  

Will Novo Nordisk Get Lift From Gut-Brain Axis?

Experts think GLP-1s in neurodegeneration may be Novo Nordisk’s next opportunity and await readouts from the Phase II ELAD trial in Alzheimer's disease for signals.  

Topics

UsernamePublicRestriction

Register

PS056908

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel